IDEAYA Biosciences Announces Inducement Grants

SOUTH SAN FRANCISCO, Calif. – June 27, 2025 –

IDEAYA Biosciences (NASDAQ: IDYA), a company pioneering precision medicine in oncology, has announced the granting of stock options to a newly appointed employee. The move, detailed in a statement released on June 26, 2025, underscores IDEAYA’s strategy to attract and retain top talent in the highly competitive biotech landscape.

The non-qualified stock options, totaling 95,600 shares of common stock, were granted under the company’s 2023 Employment Inducement Incentive Award Plan, specifically designed to incentivize individuals joining the company. This approach is in line with Nasdaq Listing Rule 5635(c)(4), which governs the use of equity as a recruitment tool.

The options come with an exercise price of $22.29 per share, reflecting the closing price of IDEAYA’s stock on The Nasdaq Global Select Market on the grant date. The terms offer a 10-year window for exercise and a vesting schedule designed to foster long-term commitment. Employees will see 25% of their options vest on the first anniversary of the vesting commencement date, with the remaining 75% vesting in equal monthly installments over the following three years, contingent on continued employment.

About IDEAYA Biosciences

IDEAYA is carving a niche in the precision medicine oncology space. The company is focused on developing targeted therapies for specific patient populations, guided by in-depth molecular diagnostics. Their strategy bridges the gap between cutting-edge biomarker identification and targeted drug discovery, aiming to deliver therapies tailored to those most likely to benefit. Their work in synthetic lethality, a burgeoning area of precision medicine, positions them at the forefront of innovation in cancer treatment.

View original content to download multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302492990.html

SOURCE IDEAYA Biosciences, Inc.